10/12/04Notice Under Section 708A (5) 6/12/04Notice of General Meeting 3/12/04Appendix 3B - Issues and Conversion of Securities 1/12/04US Approval of FerriScan Closer with FDA 510(k) submission 26/11/04Results of Annual General Meeting 25/11/04Annual General Meeting Presentation 25/11/04Company Update - Letter to Optionholders 25/11/04Company Update - Letter to Shareholders 23/11/04TGA to list FerriScan for Australia with Reciprocal Access to CE Mark and European Markets23/11/2004$1 Million Placement for First Stage FerriScan Rollout 5/11/2004New Liver Test to be Developed following BIF Grant 3/11/2004Response to ASX query re: Appendix 4C 30/09/2004Annual Report 31/08/2004Appendix 4E - Preliminary Final Report Year End 30 June 2004 30/07/2004Commitments Test Entity - Fourth Quarter Report20/07/2004FerriScan Inv recognized for Excellence in Breakthrough Tech 12/07/2004 Change of Director's Interest Notice x412/07/2004 Appendix 3B - Incentive Option Scheme 02/06/2004Transfer of Share Registry 18/05/2004Change of Director's Interest Notice 17/05/2004Response to ASX Query re Appendix 4C 14/05/2004 Appointment of Dr James Williams as Chief Executive Officer 13/05/2004Results of Meeting29/04/2004Commitments Test Entity - Third Quarter Report15/04/2004Appointment of Joint Company Secretary13/04/2004TGA Submission for FerriScan Lodged05/04/2004Letter to Shareholders: Important Commercial Success05/04/2004IVB Signs Agreement with Novartis Pharma 02/04/2004Appendix 3B - Exercise of options 31/03/2004TGA on track ASX Announcement 24/03/2004Medtel ASX Announcement23/03/2004Company Update - Newsletter to Shareholders 12/03/2004Letter to Shareholders: Share Purchase Plan/Appendix 3B 27/02/2004Half Yearly Report & Half Year Accounts 25/02/2004Distribution schedule of options 25/02/2004Top 20 holders of new options 25/02/2004Appendix 3B - Exercise of options27/01/2004Commitments Test Entity - Second Quarter Report 07/01/2004App 3B - Satisfy co. obligations re Implementation Agreement 06/01/2004Response to ASX Query re: Share Price